

# RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Giacomo Coltro,<sup>1,2,\*</sup> Giada Rotunno,<sup>1,2,\*</sup> Lara Mannelli,<sup>1-3</sup> Carmela Mannarelli,<sup>1,2</sup> Sara Fiaccabrino,<sup>1,2</sup> Simone Romagnoli,<sup>1,2,4</sup> Niccolò Bartalucci,<sup>1,2</sup> Enrica Ravenda,<sup>1,2</sup> Eleonora Gelli,<sup>2,5</sup> Emanuela Sant'Antonio,<sup>1,2</sup> Mrinal M. Patnaik,<sup>6</sup> Ayalew Tefferi,<sup>6</sup> Alessandro M. Vannucchi,<sup>1,2</sup> and Paola Guglielmelli<sup>1,2</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; <sup>2</sup>Center of Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; <sup>3</sup>Department of Medical Genetics, University of Siena, Siena, Italy; <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy; <sup>5</sup>Faculty of Medicine and Surgery, University of Florence, Florence, Italy; and <sup>6</sup>Division of Hematology, Mayo Clinic, Rochester, MN

## Key Points

- *RAS/CBL* mutations are associated with adverse phenotypic features and survival outcomes in myelofibrosis.
- *RAS/CBL* mutations are independent predictors of a reduced response to JAK inhibitors.

The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF). Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select mutations (MTs) have been associated with impaired outcomes and are currently incorporated in molecularly annotated prognostic models. Mutations of RAS/MAPK pathway genes are frequently reported in cancer and at low frequencies in MF. In this study, we investigated the phenotypic, prognostic, and therapeutic implications of *NRAS*<sup>MTs</sup>, *KRAS*<sup>MTs</sup>, and *CBL*<sup>MTs</sup> (*RAS/CBL*<sup>MTs</sup>) in 464 consecutive MF patients. A total of 59 (12.7%) patients had *RAS/CBL*<sup>MTs</sup>: *NRAS*<sup>MTs</sup>, *n* = 25 (5.4%); *KRAS*<sup>MTs</sup>, *n* = 13 (2.8%); and *CBL*<sup>MTs</sup>, *n* = 26 (5.6%). Patients with *RAS/CBL*<sup>MTs</sup> were more likely to present with high-risk clinical and molecular features. *RAS/CBL*<sup>MTs</sup> were associated with inferior overall survival compared with patients without MTs and retained significance in a multivariate model, including the Mutation-Enhanced International Prognostic Score System (MIPSS70) risk factors and cytogenetics; however, inclusion of *RAS/CBL*<sup>MTs</sup> in molecularly annotated prognostic models did not improve the predictive power of the latter. The 5-year cumulative incidence of leukemic transformation was notably higher in the *RAS/CBL*<sup>MT</sup> cohort. Among 61 patients treated with JAKis and observed for a median time of 30 months, the rate of symptoms and spleen response at 6 months was significantly lower in the *RAS/CBL*<sup>MT</sup> cohort. Logistic regression analysis disclosed a significant inverse correlation between *RAS/CBL*<sup>MTs</sup> and the probability of achieving a symptom or spleen response that was retained in multivariate analysis. In summary, our study showed that *RAS/CBL*<sup>MTs</sup> are associated with adverse phenotypic features and survival outcomes and, more important, may predict reduced response to JAKis.

## Introduction

Myelofibrosis (MF) is a clonal stem cell–derived myeloproliferative neoplasm (MPN) characterized by chronic myeloproliferation with atypical megakaryocytic hyperplasia, abnormal cytokine expression, and an intense bone marrow (BM) stromal reaction leading to BM failure and extramedullary hematopoiesis.<sup>1</sup> It can arise de novo (primary MF [PMF]) or secondary to polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). Clinical manifestations include anemia, leukoerythroblastosis, hepatosplenomegaly, debilitating constitutional symptoms, cachexia, thromboembolism, and bleeding.

Submitted 27 April 2020; accepted 6 July 2020; published online 10 August 2020.  
DOI 10.1182/bloodadvances.2020002175.

\*G.C. and G.R. contributed equally to this study.

Original data are available by e-mail request to the corresponding author, Alessandro M. Vannucchi (amvannucchi@unifi.it).

The full-text version of this article contains a data supplement.

© 2020 by The American Society of Hematology

Leukemic transformation (LT) occurs in ~14% of patients with PMF and represents a major cause of death.<sup>2</sup> Somatic phenotypic driver mutations (MTs) in *JAK2*, *MPL*, and *CALR* are found in 60%, 5%, and 20% of cases, respectively, and all lead to dysregulated JAK/STAT signaling, which normally participates in hematopoiesis and cytokine and growth factor production.<sup>3,4</sup> Recently, comprehensive mutational studies based on next-generation sequencing (NGS) in patients with MF identified recurrent mutated genes involved in epigenetic regulation, pre-messenger RNA (mRNA) splicing, cell signaling, transcription regulation, and response to DNA damage.<sup>5</sup> Some mutated genes, including *ASXL1*, *EZH2*, *IDH1/2*, *SRSF2*, and *U2AF1*, are associated with a dismal prognosis for overall survival (OS) and/or leukemia-free survival (LFS).<sup>6,7</sup> These high-molecular-risk MTs (HMR<sup>MTs</sup>) were incorporated in molecularly annotated prognostic models, such as the Mutation-Enhanced International Prognostic Score System, without (MIPSS70) or with (MIPSS70-plus) cytogenetic information.<sup>8,9</sup> The discovery of dysregulated JAK/STAT signaling as a central pathogenetic mechanism of MPN facilitated the development of small-molecule inhibitors of JAK2 (JAKis) that have shown efficacy in preclinical and clinical studies. Ruxolitinib and fedratinib are oral JAK1 and JAK2 inhibitors, approved for the treatment of MF.<sup>10-13</sup> However, JAKis do not eradicate the MPN clone, suggesting limited disease-modifying potential; furthermore, resistance leading to loss of clinical response has been reported in a substantial proportion of patients.<sup>10,11,14,15</sup>

The RAS/RAF/MEK/ERK/MAPK (RAS/MAPK) pathway comprises several components, with kinase activity involved in many cellular functions, including cell proliferation, differentiation, and migration; nuclear transport; mRNA processing; and protein translation.<sup>16</sup> Gain-of-function MTs in RAS/MAPK pathway members are common in human cancer and in nonmalignant diseases. Accordingly, the RAS/MAPK pathway is considered a potential therapeutic target, and recently, several small-molecule inhibitors have been shown to be clinically valuable, with manageable side effects. Furthermore, some studies have elucidated a functional interplay between the JAK/STAT and RAS/MAPK pathways that contributes to uncontrolled cell growth, leukemogenesis, and eventually drug resistance.<sup>17-20</sup>

In the current study we investigated the phenotypic, prognostic, and therapeutic implications of MTs in the RAS/MAPK pathway in a large population of patients with MF.

## Methods

After approval by the Institutional Review Board of Azienda Ospedaliero-Universitaria Careggi (Florence, Italy), patients with a diagnosis of prefibrotic PMF (pre-PMF), overt PMF, post-PV MF or post-ET MF were included in the current study. The diagnosis was retrospectively confirmed according to the 2016 World Health Organization (WHO) criteria for PMF and the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for post-PV and -ET MF.<sup>1,21</sup> All patients underwent mutational analysis for driver MTs and targeted NGS for 29 myeloid-relevant genes in DNA from peripheral blood (PB) granulocytes collected at the time of diagnosis or first referral, as described.<sup>8</sup> RAS/MAPK pathway genes included in the NGS panel encompassed *NRAS*, *KRAS*, and *CBL* (referred as *RAS/CBL* hereinafter), because they have been identified as the most commonly mutated genes in hematological malignancies. *CBL*

encodes for a multifunctional adaptor protein with ubiquitin ligase (E3), and MTs are associated with stabilization of receptor tyrosine kinases, resulting in constitutive activation of the RAS/MPAK pathway. *PTPN11* and *NF1* were not included in the analysis because of the low number of patients with annotated sequencing data in our series, and the very low occurrence of MTs in other series.<sup>22</sup> Statistical analyses included clinical and laboratory parameters, obtained at diagnosis or first referral, that in 90% of cases coincided with sample collection for mutation analysis. Continuous variables were presented as the median (range) and categorical variables as the frequency (percentage). Differences in the distribution of continuous variables in the categories were compared by the Mann-Whitney *U* test. The  $\chi^2$  test was used for comparison of categorical variables. The response to JAKis was evaluated according to the revised response criteria for MF defined by the IWG-MRT and European LeukemiaNet (ELN).<sup>23</sup> Logistic regression analysis was used to identify predictors of response to JAKis at 6 months. In cases of complete or quasicomplete separation, Firth's logistic regression method was used to cope with the bias of maximum-likelihood estimates. OS analysis was computed from the date of MF diagnosis to date of death (uncensored) or last contact (censored). The Kaplan-Meier method was used to prepare OS curves, which were compared by the log-rank test. The cumulative incidence (Cul) of LT was calculated after competing risk analysis and compared between groups by using Gray's test. Cox proportional hazards analysis followed by backward stepwise selection was used for univariate and multivariate analyses.  $P < .05$  indicated significant results. Comparison of relative predictive power was performed with the Akaike information criterion and area under the curve of time-dependent receiver operating characteristic curve. The JMP Pro 14.1.0 software from SAS Institute (Cary, NC), R software version 3.6.2, and Prism 8.3.0 (GraphPad, San Diego, CA) were used for calculations.

## Results

### Characteristics of study population

Four hundred sixty-four patients with WHO-defined MF (diagnosed from 1994 through 2019) were included in the study: 132 (29%) pre-PMF, 155 (33%) overt PMF, and 177 (38%) post-PV/ET MF. Tables 1 and 2 summarize prominent clinical, laboratory, and molecular characteristics of the study population. The median age at diagnosis was 60 (range 18-90) years, and 277 (60%) of the patients were men. With regard to phenotype driver MTs, *JAK2*<sup>MT</sup> was detected in 289 (62%) patients, *CALR*<sup>MT</sup> in 115 (25%), and *MPL*<sup>MT</sup> in 32 (7%), whereas 41 (9%) were triple negative. Among co-occurring MTs, the most frequently mutated genes were *ASXL1* (33%), *TET2* (20%), *EZH2* (9%), *SRSF2* (8%), and *ZRSR2* (8%) (Figure 1A; supplemental Figure 1A-C). One or more HMR<sup>MTs</sup> were found in 178 (38%) patients, with 62 (13%) harboring  $\geq 2$  HMR<sup>MTs</sup>. Cytogenetic data were available in 334 (72%) patients: 281 (84%), 31 (9%), and 22 (7%) had favorable, unfavorable, and high-risk karyotype, respectively, according to the revised cytogenetic risk stratification.<sup>24</sup>

### Frequency, distribution, and phenotypic correlates of *RAS/CBL*<sup>MTs</sup>

A total of 59 patients (12.7%) had MTs in RAS/MAPK pathway genes: *NRAS*<sup>MT</sup> was identified in 25 (5.4%), *KRAS*<sup>MT</sup> in 13 (2.8%),

**Table 1. Clinical and laboratory features of 464 patients with WHO-defined MF, stratified by presence or absence of RAS/CBL<sup>MT</sup>**

Variable	All patients (N = 464)	RAS/CBL <sup>WT</sup> (n = 405; 87%)	RAS/CBL <sup>MT</sup> (n = 59; 13%)	P (RAS/CBL <sup>WT</sup> vs RAS/CBL <sup>MT</sup> )
<b>WHO 2016 diagnosis, n (%)</b>				
Overt PMF	155 (33)	120 (30)	35 (58)	<.0001
Pre-PMF	132 (29)	120 (30)	12 (20)	
Post-PV/ET MF	177 (38)	165 (40)	12 (22)	
Male sex, n (%)	277 (60)	236 (58)	41 (69)	.10
Age at diagnosis, median (range), y	60 (18-90)	60 (18-90)	64 (24-88)	.0235
Age at diagnosis >65 y, n (%)	172 (37)	145 (36)	27 (46)	.14
Leukocytes, median (range), ×10 <sup>9</sup> /L [412]	8.9 (0.6-250)	8.8 (0.6-250)	11.7 (2.1-90.8)	.08
Leukocytes >25 × 10 <sup>9</sup> /L, n (%)	42 (10)	30 (8)	12 (23)	.0010
Hemoglobin, median (range), g/dL [415]	11.9 (4.2-17.5)	12 (4.2-17.5)	10.6 (5.4-17.3)	.0016
Hemoglobin <10 g/dL, n (%)	99 (24)	79 (22)	20 (39)	.0060
RBC transfusion dependence, n (%) [462]	141 (31)	111 (28)	30 (52)	.0002
Platelets, median (range), ×10 <sup>9</sup> /L [417]	354 (10-1800)	370 (10-1800)	270 (14-1635)	.0031
Platelets <100 × 10 <sup>9</sup> /L, median (range)	41 (10)	32 (9)	9 (18)	.0454
Peripheral CD34 <sup>+</sup> , median (range), % [335]	0.3 (0-22.2)	0.3 (0-22.2)	1.2 (0-16.7)	.0003
PB blasts, median (range), % [426]	0 (0-18)	0 (0-18)	1 (0-16)	<.0001
PB blasts ≥1%, n (%)	105 (25)	79 (21)	26 (48)	<.0001
PB blasts ≥5%, n (%)	14 (3)	6 (2)	8 (15)	<.0001
BM fibrosis grade ≥2, median (range) [438]	301 (69)	258 (67)	43 (80)	.06
Splenomegaly, n (%) [428]	348 (81)	299 (80)	49 (88)	.20
Constitutional symptoms, n (%) [463]	172 (37)	141 (35)	31 (53)	.0088
Extramedullary hematopoiesis, n (%) [449]	19 (4)	13 (3)	6 (10)	.0132
<b>IPSS risk stratification, n (%) [400]</b>				
Low risk	118 (29)	112 (32)	6 (12)	Reference
Intermediate-1 risk	127 (32)	117 (34)	10 (20)	.38
Intermediate-2 risk	78 (20)	61 (17)	17 (33)	.0004
High risk	77 (19)	59 (17)	18 (35)	.0001
<b>DIPSS risk stratification, n (%) [400]</b>				
Low risk	118 (29)	112 (32)	6 (12)	Reference
Intermediate-1 risk	175 (44)	156 (45)	19 (37)	.08
Intermediate-2 risk	87 (22)	67 (19)	20 (39)	.0001
High risk	20 (5)	14 (4)	6 (12)	.0003
<b>MIPSS70 risk stratification, n (%) [382]</b>				
Low risk	84 (22)	82 (24)	2 (4)	Reference
Intermediate risk	196 (51)	179 (54)	17 (36)	.06
High risk	102 (60)	73 (22)	29 (60)	<.0001
Deaths, n (%) [463]	172 (37)	126 (31)	46 (78)	<.0001
Leukemic transformation, n (%) [463]	57 (12)	36 (10)	21 (36)	<.0001

Bold *P* values indicate statistically significant results. The numbers in brackets indicate the number of patients with evaluable data. BM, bone marrow; RBC, red blood cell.

and CBL<sup>MT</sup> in 26 (5.6%) (Figure 1B; supplemental Figure 1A-C). A total of 27 NRAS<sup>MTs</sup> were identified, with 2 patients harboring 2 different MTs (supplemental Figure 2A). All were missense variants, with the mutational hotspot at residue G12 affected in 18 (67%) cases, whereas the mutational hotspots G13 and Q61 were affected in 2 (7%) patients each. Of the 13 KRAS<sup>MTs</sup> found in the cohort, all but 1 (a splice site variant) were missense, 4 (31%) were localized at the mutational hotspot at residue G12,

and 5 (38%) affected the highly conserved residue A146 (supplemental Figure 2B). CBL<sup>MTs</sup> were more heterogeneous, including missense (n = 24), nonsense (n = 1), and frameshift (n = 1) variants, and were enriched in exons 8 and 9 coding the linker region and RING finger domain (supplemental Figure 2C). No specific mutational hotspots were identified, although there were multiple amino acid residues affected by ≥3 MTs, such as C381 (n = 3), C384 (n = 5), and R420 (n = 4). Three patients

**Table 2. Mutational and cytogenetic features of 464 patients with WHO-defined MF, stratified by presence or absence of *RAS/CBL*<sup>MT</sup>**

Variable	All patients (N = 464)	<i>RAS/CBL</i> <sup>WT</sup> (n = 405; 89%)	<i>RAS/CBL</i> <sup>MT</sup> (n = 59; 11%)	P ( <i>RAS/CBL</i> <sup>WT</sup> vs <i>RAS/CBL</i> <sup>MT</sup> )
<b>MPN drivers, n (%)</b>				
<i>JAK2</i> <sup>M</sup>	289 (62)	258 (64)	31 (53)	.09
<i>CALR</i> <sup>M</sup>	115 (25)	101 (25)	14 (24)	.90
<i>MPL</i> <sup>M</sup>	32 (7)	28 (7)	4 (7)	.99
Triple negative	41 (9)	30 (7)	11 (19)	<b>.0045</b>
<b>Epigenetic regulators of methylation, n (%)</b>				
<i>DNMT3A</i> <sup>M</sup>	25 (5)	23 (6)	2 (3)	.47
<i>IDH1/2</i> <sup>M</sup>	15 (3)	11 (3)	4 (7)	.10
<i>TET2</i> <sup>M</sup>	91 (20)	79 (20)	12 (20)	.88
<b>Chromatin regulating genes, n (%)</b>				
<i>ASXL1</i> <sup>M</sup>	153 (33)	111 (27)	42 (71)	<b>&lt;.0001</b>
<i>EZH2</i> <sup>M</sup> [463]	41 (9)	29 (7)	12 (20)	<b>.0009</b>
<b>Pre-mRNA splicing mutations, n (%)</b>				
<i>SF3B1</i> <sup>M</sup> [461]	30 (7)	24 (6)	6 (11)	.17
<i>SRSF2</i> <sup>M</sup>	35 (8)	23 (6)	12 (20)	<b>&lt;.0001</b>
<i>U2AF1</i> <sup>M</sup> [461]	25 (5)	20 (5)	5 (9)	.22
<i>ZRSR2</i> <sup>M</sup> [318]	26 (8)	21 (7)	5 (14)	.21
<b>Transcription factors and nucleosome assembly, n (%)</b>				
<i>NF-E2</i> <sup>M</sup> [445]	24 (5)	24 (6)	0 (0)	.07
<i>RUNX1</i> <sup>M</sup> [461]	15 (3)	12 (3)	3 (5)	.34
<i>SETBP1</i> <sup>M</sup> [318]	7 (2)	4 (1)	3 (8)	<b>.0092</b>
<b>Cell signaling, n (%)</b>				
<i>CSF3R</i> <sup>M</sup> [318]	8 (3)	8 (3)	0 (0)	.30
<i>KIT</i> <sup>M</sup> [460]	4 (1)	3 (1)	1 (2)	.43
<i>SH2B3/LNK</i> <sup>M</sup> [458]	19 (4)	15 (4)	4 (7)	.23
<b>DNA damage response, n (%)</b>				
<i>TP53</i> <sup>M</sup> , n (%) [462]	22 (5)	20 (5)	2 (4)	.64
<b>HMR<sup>MT</sup>, n (%)*</b>				
HMR <sup>MT</sup> [463]	178 (38)	134 (33)	44 (75)	<b>&lt;.0001</b>
≥2 HMR <sup>MTs</sup> [463]†	62 (13)	37 (9)	25 (42)	<b>&lt;.0001</b>
<b>Cytogenetics, n (%)‡</b>				
Abnormal karyotype [334]	112 (34)	96 (33)	16 (36)	.67
Favorable karyotype	281 (84)	248 (85)	33 (75)	Reference
Unfavorable karyotype	31 (9)	25 (9)	6 (14)	.22
Very high-risk karyotype	22 (7)	17 (6)	5 (11)	.13

Bold *P* values indicate statistically significant results. Numbers in brackets are the number of patients with evaluable data.


\*The HMR category is defined as the presence of a mutation in any of the following genes: *ASXL1*, *EZH2*, *SRSF2*, and *IDH1/2*.

†≥2 HMR<sup>MTs</sup> indicates the presence of 2 or more mutations in the *ASXL1*, *EZH2*, *SRSF2*, and *IDH1/2* genes (2 or more mutations in the same gene are counted as 1).

‡According to the revised cytogenetic risk stratification.<sup>24</sup>

had both *NRAS*<sup>MT</sup> and *KRAS*<sup>MT</sup>, 2 patients had MTs in both *NRAS* and *CBL*. The median variant allelic fraction (VAF) of all *RAS/CBL*<sup>MTs</sup> (evaluable n = 60) was 30% (range, 2%-93%), which was significantly lower than the VAF of driver MTs; namely, *JAK2*<sup>V617F</sup> (46%; *P* < .0001), *CALR*<sup>MT</sup> (52%; *P* < .0001), and *MPL*<sup>MT</sup> (54%; *P* < .0001; supplemental Figure 3A). The median VAF of *NRAS*<sup>MTs</sup>, *KRAS*<sup>MTs</sup>, and *CBL*<sup>MTs</sup> was 24% (range, 3%-51%), 24% (range, 2%-52%), and 36% (range 5%-93%), with a trend of the *CBL*<sup>MT</sup> VAF that was higher than the *NRAS*<sup>MT</sup> and *KRAS*<sup>MT</sup> VAFs (supplemental Figure 3B).

Main clinical, laboratory, and molecular characteristics of the study population stratified by the presence or absence of *RAS/CBL*<sup>MTs</sup> are listed in Tables 1 and 2. In comparison with their wild-type (WT) counterparts, patients with *RAS/CBL*<sup>MTs</sup> were more likely to be diagnosed with overt PMF than pre-PMF (*P* = .0021) or post-PV/ET MF (*P* < .0001); to be older at MF diagnosis (*P* = .0235); to have white blood cell counts >25 × 10<sup>9</sup>/L (*P* = .0010), lower hemoglobin levels (HB; *P* = .0016), lower platelet counts (*P* = .0031), higher PB CD34<sup>+</sup> (*P* = .0003), and higher PB blasts (*P* < .0001); to have constitutional symptoms (*P* = .0088) and red



**Figure 1. Distribution, molecular landscape and survival correlates of *RAS/CBL*<sup>MTs</sup>.** (A) The frequency of gene mutations identified in the MF cohort; red-violet bars identify mutations of the RAS/MAPK pathway genes (ie, *NRAS*, *KRAS*, and *CBL*). (B) Aerogram displaying the percentage of patients with MF, with and without *RAS/CBL*<sup>MTs</sup> (left), and the distribution of patients with *NRAS*<sup>MTs</sup>, *KRAS*<sup>MTs</sup>, and *CBL*<sup>MTs</sup> and multiple *RAS/CBL*<sup>MTs</sup> (right). (C) Kaplan-Meier estimates of OS in the entire MF cohort by the presence or absence of *RAS/CBL*<sup>MTs</sup>. (D) Five-year Cul of leukemic transformation in the entire MF cohort by the presence or absence of *RAS/CBL*<sup>MTs</sup>.

blood cell transfusion dependence (RBC-TD) more frequently (*P* = .0002); and to develop extramedullary hematopoiesis (EMH) more frequently (*P* = .0132). With regard to driver MTs, patients with *RAS/CBL*<sup>MTs</sup> were more frequently triple negative (19% vs 7%; *P* = .0045) compared to patients with *RAS/CBL*<sup>WT</sup>. *JAK2*<sup>MT</sup> tended to be enriched in the *RAS/CBL*<sup>WT</sup> cohort (64% vs 52%; *P* = .09). Among nondriver MTs, *ASXL1*<sup>MTs</sup> (71% vs 27%;

*P* < .0001), *EZH2*<sup>MTs</sup> (20% vs 7%; *P* = .0009), *SETBP1*<sup>MTs</sup> (8% vs 1%; *P* = .0092), and *SRSF2*<sup>MTs</sup> (20% vs 6%; *P* < .0001) significantly clustered with *RAS/CBL*<sup>MTs</sup>. Overall, patients with *RAS/CBL*<sup>MTs</sup> had HMR<sup>MTs</sup> (75% vs 33%; *P* < .0001) and >1 HMR<sup>MT</sup> (42% vs 9%; *P* < .0001) more frequently. There was no difference in the distributions of karyotype abnormalities and cytogenetic risk stratification. Considering clinical and molecular



**Table 3. Results of multivariate Cox proportional hazards model of OS**

Covariate	Primary and secondary MF		Overt PMF		Pre-PMF		Post-PV/ET MF	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Constitutional symptoms	NS		NS		NS		NS	
Leukocytes >25 × 10 <sup>9</sup> /L	4.81 (2.79-8.26)	<.0001	4.58 (1.90-11.01)	.0007	18.28 (4.69-71.21)	<.0001		
Hemoglobin <10 g/dL	2.27 (1.48-3.48)	.0002	NS		2.61 (1.01-6.81)	.0487	2.75 (1.54-4.91)	.0006
Blood blasts ≥2%	1.80 (1.10-2.96)	.0204	2.52 (1.17-5.46)	.0186	NS		2.90 (1.56-5.42)	.0008
Platelet count <100 × 10 <sup>9</sup> /L	4.79 (2.72-8.44)	<.0001	4.80 (2.09-11.00)	.0002	7.98 (2.33-27.36)	.0010	8.25 (3.45-19.74)	<.0001
BM fibrosis grade ≥2	NS		—		—		—	
Absence of CALR1-like	NS		NS		NS		NS	
HMR <sup>MT*</sup>	1.86 (1.24-2.80)	.0029	NS		11.16 (3.53-35.28)	<.0001	NS	
≥2 HMR <sup>MTs†</sup>	NS		NS		NS		NS	
RAS/CBL <sup>MT</sup>	1.73 (1.10-2.71)	.0177	2.91 (1.54-5.50)	.0010	NS		NS	
<b>Cytogenetics‡</b>								
Favorable	Reference		Reference		Reference		Reference	
Unfavorable	NS		2.39 (1.08-5.28)	.0314	NS		NS	
Very high risk	4.25 (2.27-7.98)	<.0001	10.82 (3.57-32.76)	<.0001	20.33 (4.58-90.31)	<.0001	NS	

NS, not significant.

\*The HMR category is defined as the presence of a mutation in any of the following genes: *ASXL1*, *EZH2*, *SRSF2*, and *IDH1/2*.

†≥2 HMR<sup>MTs</sup> indicate the presence of 2 or more mutations in the *ASXL1*, *EZH2*, *SRSF2*, and *IDH1/2* genes (2 or more mutations in the same gene are counted as 1).

‡According to the revised cytogenetic risk stratification.<sup>24</sup>

prognostic models, the *RAS/CBL*<sup>MT</sup> cohort was enriched in patients with higher risk disease per the International Prognostic Score System (IPSS), the Dynamic IPSS (DIPSS), and the MIPSS70.

### Survival correlates of *RAS/CBL*<sup>MTs</sup>

The median follow-up of the entire cohort was 82 (95% confidence interval [CI], 70-89) months, and 172 (37%) deaths were documented at last follow-up. Median OS was 123 (95% CI, 103-141) months. In univariate analysis, MF patients with *RAS/CBL*<sup>MTs</sup> had inferior OS compared with that of their WT counterparts ( $P < .0001$ ; hazard ratio [HR], 2.30; 95% CI, 1.63-3.24), with medians of 51 (95% CI, 31-73) and 140 (95% CI, 111-149) months, respectively (Figure 1C). In a multivariate Cox proportional hazards model that included *RAS/CBL*<sup>MTs</sup> and all risk factors in the MIPSS70, along with karyotype stratification, the former retained its significance (HR, 1.73; 95% CI, 1.10-2.71;  $P = .0177$ ; Table 3). Considering overt PMF, pre-PMF, and post-PV/ET MF separately, the respective median OSs were 103 (95% CI, 66-131), 193 (95% CI, 124 to not reached [NR]), and 114 (95% CI, 87-145) months. The presence of *RAS/CBL*<sup>MTs</sup> was associated with inferior OS in overt PMF (median OS, 55 vs 110 months;  $P = .0106$ ; HR, 2.0; 95% CI, 1.2-3.2) and pre-PMF (median OS, 31 vs 193 months;  $P < .0001$ ; HR, 6.0; 95% CI, 2.7-13.4) cohorts, but not in post-PV/ET MF (supplemental Figure 4A-C). Upon multivariate Cox proportional hazards analysis, the negative survival impact of *RAS/CBL*<sup>MTs</sup> was retained in overt PMF only (HR, 2.91; 95% CI, 1.54-5.50;  $P = .0010$ ; Table 3).

At last follow-up, 57 (12%) patients had transformed to acute leukemia. Overall, LT was significantly more frequent in the *RAS/CBL*<sup>MT</sup> cohort (36% vs 9%;  $P < .0001$ ) compared with the unmutated counterpart, and this finding was confirmed in all 3 MF subtypes (overt PMF, 34% vs 10%,  $P = .0005$ ; pre-PMF, 42% vs

5%,  $P < .0001$ ; post-PV/ET MF, 33% vs 11%,  $P = .0238$ ). After competing risk analysis, the 5-year Cul of LT for the entire MF cohort was 12% (95% CI, 9-16) and was significantly higher in patients with *RAS/CBL*<sup>MTs</sup> than in those with *RAS/CBL*<sup>WT</sup> ( $P < .0001$ ), with respective values of 29% (95% CI, 18-42) and 9% (95% CI, 6-12; Figure 1D). By disease subtype, the 5-year Cul of LT was still significantly higher in patients with *RAS/CBL*<sup>MTs</sup> vs those with *RAS/CBL*<sup>WT</sup> who had overt PMF (24% [95% CI, 11-40] vs 8% [95% CI, 4-15], respectively;  $P = .0066$ ) and pre-PMF (45% [95% CI, 14-73] vs 8% [95% CI, 4-16], respectively;  $P = .0003$ ; supplemental Figure 5A-C).

To evaluate the prognostic contribution of *RAS/CBL*<sup>MTs</sup> to risk stratification of MF patients, we recomputed MIPSS70 and MIPSS70-plus scores after embedding *RAS/CBL*<sup>MTs</sup> as HMR<sup>MTs</sup>, along with *ASXL1*<sup>MTs</sup>, *EZH2*<sup>MTs</sup>, *IDH1/2*<sup>MTs</sup>, and *SRSF2*<sup>MTs</sup>. This attempt produced only minimal redistribution of MF patients across the 3/4 risk classes (supplemental Figure 6A-B), most likely because *RAS/CBL*<sup>MTs</sup> are frequently associated with clinical and molecular features that per se define a higher risk disease. We further compared the statistical power of the standard and *RAS/CBL*-enhanced MIPSS70 and MIPSS70-plus in predicting OS and LFS, using the Akaike information criterion and the 3-year receiver operating characteristic area under the curve. We found no significant difference between the standard and modified MIPSS70/MIPSS70-plus (supplemental Figure 6C), suggesting that *RAS/CBL*<sup>MTs</sup> do not add prognostically meaningful information to current molecularly annotated models.

### *RAS/CBL*<sup>MTs</sup> and response to JAKi treatment

In total, 121 of 464 patients (26%) received treatment with a JAKi at any time during the disease course, 61 of whom (50%) were treated in the context of a clinical trial, with treatment response that was fully evaluable across the entire treatment period according to the

revised IWG-MRT/ELN<sup>23</sup> response criteria. Fifty-seven patients were treated with ruxolitinib, 1 each with pacritinib and momelotinib, and 2 with different JAKi administered sequentially (pacritinib-ruxolitinib and ruxolitinib-momelotinib). Most patients had serial NGS analysis, performed at baseline and different time points, including at time of loss of response. At baseline, *RAS/CBL*<sup>MTs</sup> were present in 9 (15%) patients, whereas 5 (8%) acquired *RAS/CBL*<sup>MTs</sup> during JAKi treatment. The median daily dose intensity of ruxolitinib was 30 mg for *RAS/CBL*<sup>WT</sup> and 25.4 mg for *RAS/CBL*<sup>MT</sup> patients ( $P = .82$ ).

After a median treatment time of 30 (range, 3-120) months, an anemia response was achieved by 4 (8%) patients at any time of treatment, and all were *RAS/CBL*<sup>WT</sup>. Fifty-five (90%) patients achieved a symptom response after a median time of 1 (0-26) month from JAKi start. The rate of symptom response was significantly lower in patients with *RAS/CBL*<sup>MTs</sup> than in their counterparts without MTs (67% vs 94%;  $P = .0104$ ). At month 6 of treatment, a symptom response was obtained by 47 (77%) patients, including 4 (9%) with *RAS/CBL*<sup>MT</sup> and 43 (91%) without ( $P = .0118$ ). In univariate regression logistic analysis, *RAS/CBL*<sup>MTs</sup> at baseline correlated significantly with a lower probability of achieving symptom response at 6 months (odds ratio [OR], 0.17; 95% CI, 0.04-0.75;  $P = .0194$ ). The same held true for absence of the *JAK2*<sup>MT</sup> ( $P = .0054$ ) and presence of *CALR*<sup>MT</sup> ( $P = .0352$ ; Figure 2A, top). In multivariate analysis, only *RAS/CBL*<sup>MTs</sup> (OR, 0.17; 95% CI, 0.03-0.86;  $P = .0323$ ) and absence of *JAK2*<sup>MT</sup> (OR, 6.85; 95% CI, 1.63-28.85;  $P = .0087$ ) remained independent predictors of an inferior symptom response at 6 months (Figure 2A, bottom).

A total of 34 (59%) patients with splenomegaly achieved a  $\geq 50\%$  reduction from baseline in palpable splenic length at any time during the treatment period. At month 6 of treatment, a spleen response was observed in 29 (51%) patients. Notably, no patients with baseline *RAS/CBL*<sup>MTs</sup> achieved a significant reduction in splenic volume at any time during the treatment course, whereas the rate of spleen response among patients with *RAS/CBL*<sup>WT</sup> was 59% at month 6 ( $P = .0019$ ) and 68% at any time ( $P = .0003$ ). Univariate logistic regression analysis disclosed a significant inverse correlation between *RAS/CBL*<sup>MTs</sup> and the probability of achieving a spleen response at 6 months (by Firth's method: OR, 0.04; 95% CI, 0.01-0.36;  $P = .0014$ ), with other factors, including baseline HB  $< 10$  g/dL ( $P = .0396$ ), splenomegaly  $> 10$  cm from the left costal margin ( $P = .0076$ ), DIPSS intermediate-2/high ( $P = .0247$ ), *ASXL1*<sup>MTs</sup> ( $P = .0032$ ), and presence of *HMR*<sup>MTs</sup> ( $P = .0067$ ) (Figure 2B; top). Upon multivariate Firth's logistic regression analysis, *RAS/CBL*<sup>MTs</sup> (OR, 0.04; 95% CI, 0.01-0.46;  $P = .0061$ ), baseline splenomegaly  $> 10$  cm from the left costal margin (OR, 0.21; 95% CI, 0.04-0.85;  $P = .0283$ ), and *ASXL1*<sup>MTs</sup> (OR, 0.21; 95% CI, 0.07-0.90;  $P = .0333$ ) remained significantly associated with a lower probability of spleen response at 6 months (Figure 2B; bottom). Two patients who obtained a spleen response developed *KRAS*<sup>MT</sup> during the treatment course, and in both, the response was lost shortly before or after detection of the MT. Time to response, rate of loss, and duration of spleen response were not significantly different among patients with *RAS/CBL*<sup>MTs</sup> or those with *RAS/CBL*<sup>WT</sup>. Overall, primary resistance (defined as the lack of either anemia, symptoms, or spleen response) was much more frequent in patients with *RAS/CBL*<sup>MTs</sup>, either at baseline or during JAKi treatment (29% vs 2%;  $P = .0015$ ).

Among JAKi-treated patients, the presence of *RAS/CBL*<sup>MTs</sup>, either at JAKi start or during treatment, was associated with a significantly inferior OS (computed from the date of JAKi start), with respective median values of 30.4 (95% CI, 11.1-71.3) and 91.4 (95% CI, 64.8-NR) months (Figure 3) for *RAS/CBL*<sup>MT</sup> and *RAS/CBL*<sup>WT</sup> patients ( $P = .0001$ ; HR, 4.57; 95% CI, 1.98-10.55). Notably, these results were confirmed after adjustment for the IPSS and DIPSS scores at baseline. Transformation to acute leukemia occurred in 6 (10%) patients after a median of 51 (range, 5-120) months from JAKi start, and 4 (67%) were *RAS/CBL*<sup>MT</sup> ( $P = .0073$ ): 3 had *RAS/CBL*<sup>MTs</sup> at baseline, and 1 acquired an *NRAS*<sup>MT</sup> during JAKi treatment.


## Discussion

In the current study, we provided a comprehensive analysis of phenotypic, prognostic, and therapeutic correlates of *RAS/CBL*<sup>MTs</sup> in a large cohort of molecularly annotated patients with MF. Overall, pathogenic MTs in the *RAS*/MAPK pathway were identified in 12.7% of cases, with *NRAS*<sup>MTs</sup>, *KRAS*<sup>MTs</sup>, and *CBL*<sup>MTs</sup> accounting for 5.4%, 2.8%, and 5.6%, respectively. Our findings are consistent with those in previous studies<sup>5,25</sup> and revealed *RAS*/MAPK to be a frequently involved pathway in MF pathobiology. Most MTs were missense and localized at previously known hotspots in the 3 genes. Notably, we found no *KRAS*<sup>G12C</sup> mutations, which is a variant that is specifically targeted by 2 inhibitors currently in development (AMG 510 and MRTX849).<sup>26,27</sup> *NRAS*<sup>MTs</sup> were more common in overt PMF, whereas *KRAS*<sup>MTs</sup> and *CBL*<sup>MTs</sup> were similarly distributed among the 3 MF subtypes. Although there were no significant differences in *NRAS*<sup>MTs</sup>, *KRAS*<sup>MTs</sup> and *CBL*<sup>MTs</sup>, the median VAFs of *RAS/CBL*<sup>MTs</sup> was significantly lower than those of the driver MTs, confirming that they represent subclonal events that are acquired during the disease course.<sup>25</sup>

*RAS/CBL*<sup>MTs</sup> were associated with distinct clinical and laboratory features that usually define high-risk disease, including higher white blood cell counts, lower HB and platelet counts, higher PB CD34<sup>+</sup> and blast counts, and higher frequency of RBC-TD and constitutional symptoms. Accordingly, most patients with MF who had the *RAS/CBL*<sup>MTs</sup> were considered to be higher risk according to current prognostic models.

On univariate analysis, the OS of patients with *RAS/CBL*<sup>MTs</sup> was significantly inferior in the entire MF cohort and, by disease subtype, in overt PMF and pre-PMF. These findings may be explained by the association of *RAS/CBL*<sup>MTs</sup> with high-risk features and *HMR*<sup>MTs</sup>. However, in a multivariate model including individual MIPSS70 risk factors and karyotype, *RAS/CBL*<sup>MTs</sup> retained an independent negative prognostic impact in overt PMF. Recently, Santos et al evaluated 723 patients with MF, and found that the *RAS/CBL*<sup>MTs</sup> are an independent predictor of inferior OS and LFS.<sup>25</sup> Our findings suggest that the shortened survival conferred by *RAS/CBL*<sup>MTs</sup> may be limited to overt PMF. Reasons for such a difference remain at present unknown and may be related in part to the low frequency of *RAS/CBL*<sup>MTs</sup> in pre-PMF, which prevented it from retaining significance in multivariate analysis.

The survival disadvantage associated with *RAS/CBL*<sup>MTs</sup> is likely related to the higher rate of LT, suggesting that MTs are molecular drivers of disease progression.<sup>28</sup> In our study, MF patients with *RAS/CBL*<sup>MTs</sup> transformed to blast-phase disease more frequently and had a significantly higher Cul of LT compared with WT patients. By disease subtype, the increased risk of blast transformation was



**Figure 2. Baseline factors associated with symptom and spleen response to JAKis.** (A) The results of univariate (top) and multivariate (bottom) logistic regression analyses of baseline factors predictive of symptom response at 6 months according to the revised IWG-MRT/ELN<sup>23</sup> in 61 patients with MF treated with JAKis. (B) The results of univariate (top) and multivariate (bottom) logistic regression analyses of baseline factors predictive of spleen response at 6 months according to the revised IWG-MRT/ELN<sup>23</sup> in 61 patients with MF treated with JAKis. Firth's logistic regression method was used to cope with the bias of maximum likelihood estimates. BL, baseline; LCM, left costal margin; MF-RUXO time interval, time interval between myelofibrosis diagnosis and initiation of JAKis.

confirmed in both overt and pre-PMF, unlike in post-PV/ET MF, remarking the differences portending the pathobiology of primary and secondary MF. Santos et al incorporated *RAS/CBL*<sup>MTs</sup> in a novel MF-specific prognostic model that predicted OS across both a training and a validation cohort.<sup>25</sup> When we integrated MIPSS0 and MIPSS70-plus models with *RAS/CBL*<sup>MTs</sup> as HMR<sup>MTs</sup>, we did not observe any risk redistribution across the models or improvement of statistical power, suggesting that *RAS/CBL*<sup>MTs</sup> do not add relevant information to current molecularly annotated prognostication systems.


Myelofibrosis treatment has been revolutionized by the use of inhibitors of JAK signaling, including ruxolitinib and fedratinib.<sup>10-13</sup> In the current study, 121 patients had received JAKis; however, we focused our analysis on the 61 who were treated in the context of a clinical trial, because response was accurately defined according to standardized criteria, and these patients, unlike the remaining ones, had serial molecular analyses, including one at the time that a loss of response was judged to have occurred. Overall, response rates were comparable with those in previous studies.<sup>29-32</sup> However, the presence of *RAS/CBL*<sup>MTs</sup> was associated with a lower probability of obtaining symptoms and spleen responses at

6 months. Notably, multivariate analysis confirmed *RAS/CBL*<sup>MTs</sup> as an independent predictor of a lesser response, along with the absence of *JAK2*<sup>MT</sup> for symptom response, palpable splenomegaly >10 cm, and *ASXL1*<sup>MTs</sup> for spleen response. Although patients with *RAS/CBL*<sup>MTs</sup> showed lower HB and platelet counts, the JAKi dose intensity was not different among patients with and without *RAS/CBL*<sup>MT</sup>, ruling out an effect of drug dose on the lower rate of response.

A few studies have assessed the impact of the molecular landscape on treatment outcomes in patients with MF treated with JAKis, but have produced inconsistent findings. In a retrospective analysis of the CONFORT-II trial, we found that spleen responses and anemia did not correlate with either driver or HMR<sup>MTs</sup>.<sup>33</sup> Another study suggested that the *JAK2*<sup>V617F</sup> VAF may predict spleen response.<sup>34</sup> Patel and colleagues<sup>35</sup> found that 1 or more HMR<sup>MTs</sup> and the presence of ≥3 MTs were associated with decreased spleen response and a shorter time to discontinuation of therapy among 95 ruxolitinib-treated patients. They also observed a trend for worse OS in patients with G12 *N/KRAS*<sup>MT</sup>. Notably, the NGS panel did not include either *SRSF* or *CBL*. Spiegel et al found that *ASXL1*<sup>MTs</sup>, *EZH2*<sup>MTs</sup>, *CBL*<sup>MTs</sup>, and HMR<sup>MTs</sup> correlated with a shorter time to



**Figure 3. Kaplan-Meier estimates of OS in 61 patients with MF treated with JAKis by the presence or absence of *RAS/CBL*<sup>MTs</sup>.**



treatment failure, although no individual MT was associated with spleen or anemia response.<sup>36</sup> Recently, we reported that loss of spleen response was associated with HMR<sup>MTs</sup> and clonal progression, whereas the absence of *ASXL1*<sup>MTs</sup> and *JAK2*<sup>V617F</sup> VAF reduction >20% at any time during treatment correlated with long-term spleen response<sup>37</sup>; notably, clonal progression was associated with shorter OS, as reported.<sup>38</sup> To the best of our knowledge, our study is the first to investigate systematically the impact of *RAS/CBL*<sup>MTs</sup> in JAKi-treated MF patients with accurate response assessment. Although further validation is needed, we believe that our findings shed light on new molecular mechanisms underlying reduced response to JAKis.

A correlation of reduction in splenic volume and length with longer survival in patients treated with ruxolitinib has been reported.<sup>32,39,40</sup> Accordingly, the inferior OS in JAKi-treated patients harboring *RAS/CBL*<sup>MTs</sup> provides further support to spleen response as a feasible predictor of superior survival in the context of therapy with a JAKi. Furthermore, our findings suggest that treatment with a JAKi does not overcome the negative prognostic impact of *RAS/CBL*<sup>MTs</sup>, in disagreement with Santos et al,<sup>25</sup> who found nonsignificant improvement of OS in patients with *RAS/CBL*<sup>MTs</sup> who were treated with ruxolitinib. Several inhibitors of the RAS/MAPK pathway are currently being investigated in hematologic malignancies. Combined inhibition of JAK2 and MEK (the intermediate kinases in the MEK/ERK pathway) by ruxolitinib and selumetinib abrogated myeloproliferative features and provided long-term survival in a *NRAS*<sup>G12D/G12D</sup> mouse model.<sup>19</sup> Gain-of-function MTs in the RAS/MAPK pathway co-occurring with *JAK2*<sup>V617F</sup> confers resistance to JAK inhibition by maintaining sustained BAD phosphorylation, resulting in specific dependence on BCL-xL for survival.<sup>41</sup> Furthermore, PDGF-BB/PDGFR $\alpha$  signaling has been implicated in JAK2-independent MEK/ERK activation in MPN, eventually contributing to bypassing of JAK2 inhibition.<sup>20</sup> Combined inhibition of JAK2 and MEK by ruxolitinib and binimetinib suppressed MEK/ERK activation in both *JAK*<sup>V617F</sup> and *MPL*<sup>W515L</sup> mutant mouse models, with increased efficacy and improved fibrosis to a greater extent, compared with JAKi monotherapy.<sup>20</sup> Our findings are consistent with a compensatory role of

MEK/ERK pathway activation in JAKi-resistance, offering a rationale for assessing combined targeting of JAK2/STAT and RAS/MAPK pathways in MPNs.

We acknowledge potential limitations in the interpretation of current findings. First, the retrospective nature of the analysis may harbor intrinsic selection biases. Second, the clustering of genes according to known, biologically relevant pathways, although it overcomes the limitations of single-gene-level analysis, cannot fully account for the complex network of relationships of pathway components and with other signaling and/or regulatory pathways. However, the particular role of the RAS/MAPK pathway in *JAK2*-driven malignancies is well established.<sup>42-44</sup> Finally, as concerns the analysis of the effect of *RAS/CBL*<sup>MTs</sup> on treatment with JAKis, although we acknowledge the lack of a validation cohort, we trust in the accuracy of our information given that all patients were prospectively followed up in the setting of controlled clinical trials.

Overall, our study revealed that *RAS/CBL*<sup>MTs</sup> are major molecular drivers in a considerable proportion of patients with MF and that they cluster with adverse phenotypic features, predict inferior OS, and are associated with a high incidence of LT. The presence of *RAS/CBL*<sup>MTs</sup> may also predict reduced symptom and spleen responses to JAKis and, by mediating drug resistance, contribute to undermining the survival advantage attributable to ruxolitinib; these findings remain to be prospectively validated. Finally, we suggest that dual targeting of the JAK/STAT and RAS/MAPK pathways represents an attractive opportunity for improving therapeutic efficacy in MPNs.

## Acknowledgments

This work was supported by research funding from Associazione Italiana per la Ricerca sul Cancro (AIRC) 5 × 1000 called “Metastatic disease: the key unmet need in oncology” to MYNERVA (MYeloid NEoplasms Research Venture AIRC; project 21267), and by the Accelerator Award Project funded through a partnership between Cancer Research UK, Fondazione AIRC, Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, and Istituto Toscano Tumori, Regione Toscana (project 2013-B16D14001130002).

## Authorship

Contributions: G.C., P.G., M.M.P., A.T., and A.M.V. designed the research, interpreted the results, and wrote and edited the final manuscript; L.M., E.R., E.S., and E.G. contributed patients; G.R., C.M., and S.F. performed the molecular research and interpreted the results; G.C., N.B., and S.R. performed the statistical analysis; and all authors read and approved the final draft of the manuscript.

Conflict-of-interest disclosure: A.M.V. is on the advisory board of Novartis, Celgene, AbbVie, Incyte, Italfarmaco, and CTI; and is a speaker for Novartis, Celgene, and CTI. P.G. is on the advisory

board and is a speaker for Novartis. M.M.P. has served on the advisory board of StemLine Pharmaceuticals. The remaining authors declare no competing financial interests.

ORCID profiles: G.C., 0000-0002-0816-5462; S.R., 0000-0001-5744-3716; N.B., 0000-0002-9328-3948; M.M.P., 0000-0001-6998-662X; A.M.V., 0000-0001-5755-0730; P.G., 0000-0003-1809-284X.

Correspondence: Alessandro M. Vannucchi, CRIMM, Dipartimento di Medicina Sperimentale e Clinica, AOU Careggi, 50134 Firenze, Italy; e-mail: amvannucchi@unifi.it.

## References

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
2. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*. 2014;124(16):2507-2513.
3. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. *Blood*. 2014;123(22):e123-e133.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7(4):387-397.
5. Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. *Blood Adv*. 2016;1(2):105-111.
6. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia*. 2013;27(9):1861-1869.
7. Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*. 2018;32(10):2274-2278.
8. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. *J Clin Oncol*. 2018;36(4):310-318.
9. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. *J Clin Oncol*. 2018;36(17):1769-1770.
10. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. 2012;366(9):799-807.
11. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. 2012;366(9):787-798.
12. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. *JAMA Oncol*. 2015;1(5):643-651.
13. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol*. 2017;4(7):e317-e324.
14. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *J Hematol Oncol*. 2017;10(1):156.
15. Meyer SC. Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms. *Hematol Oncol Clin*. 2017;31(4):627-642.
16. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. *Clin Cancer Res*. 2008;14(2):342-346.
17. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. *Leukemia*. 2008;22(4):686-707.
18. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. *Leukemia*. 2008;22(4):708-722.
19. Kong G, Wunderlich M, Yang D, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. *J Clin Invest*. 2014;124(6):2762-2773.
20. Stivala S, Codilupi T, Brkic S, et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. *J Clin Invest*. 2019;129(4):1596-1611.
21. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia*. 2008;22(2):437-438.
22. Brecqueville M, Rey J, Devillier R, et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. *Haematologica*. 2014;99(1):37-45.

23. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*. 2013;122(8):1395-1398.
24. Tefferi A, Nicolosi M, Mudireddy M, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*. 2018;32(5):1189-1199.
25. Santos FP, Getta B, Masarova L, et al. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. *Leukemia*. 2020;34(3):799-810.
26. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*. 2019;575(7781):217-223.
27. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. *Cancer Discov*. 2020;10(1):54-71.
28. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci USA*. 2014;111(50):E5401-E5410.
29. Verstovsek S, Mesa RA, Gotlib J, et al; COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica*. 2015;100(4):479-488.
30. Harrison CN, Vannucchi AM, Kiladjian J-J, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [published correction appears in *Leukemia*. 2017;31(3):775]. *Leukemia*. 2016;30(8):1701-1707.
31. Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. *Haematologica*. 2016;101(9):165-1073.
32. Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget*. 2017;8(45):79073-79086.
33. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. *Blood*. 2014;123(14):2157-2160.
34. Barosi G, Klersy C, Villani L, et al. JAK2(V617F) allele burden  $\geq 50\%$  is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. *Leukemia*. 2016;30(8):1772-1775.
35. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. *Blood*. 2015;126(6):790-797.
36. Spiegel JY, McNamara C, Kennedy JA, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. *Blood Adv*. 2017;1(20):1729-1738.
37. Pacilli A, Rotunno G, Mannarelli C, et al. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. *Blood Cancer J*. 2018;8(12):122.
38. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood*. 2017;130(9):1125-1131.
39. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. *Blood*. 2012;120(6):1202-1209.
40. Vannucchi AM, Kantarjian HM, Kiladjian J-J, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. *Haematologica*. 2015;100(9):1136-1145.
41. Winter PS, Sarosiek KA, Lin KH, et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. *Sci Signal*. 2014;7(357):ra122.
42. Dai C, Chung I-J, Krantz SB. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. *Exp Hematol*. 2005;33(2):152-158.
43. Ho JM-Y, Nguyen MH-H, Dierov JK, et al. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. *Blood*. 2002;100(4):1438-1448.
44. Khan I, Huang Z, Wen Q, et al. AKT is a therapeutic target in myeloproliferative neoplasms. *Leukemia*. 2013;27(9):1882-1890.